Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
To investigate the safety and efficacy of ofatumumab, a novel human anti-CD20 monoclonal antibody (mAb), in patients with active rheumatoid arthritis (RA) whose disease did not respond to > or = 1 disease-modifying antirheumatic drug.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Arthritis & Rheumatism |
| Vol/bind | 62 |
| Udgave nummer | 8 |
| Sider (fra-til) | 2227-38 |
| Antal sider | 12 |
| ISSN | 0004-3591 |
| DOI | |
| Status | Udgivet - 1 aug. 2010 |
ID: 34064196